Pacira Awarded New U.S. Patent Covering EXPAREL Composition
Portfolio Pulse from
Pacira Pharmaceuticals has been awarded a new U.S. patent for its EXPAREL composition, extending its intellectual property protection until 2044. This is the first in a new family of patents for EXPAREL.
December 03, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pacira Pharmaceuticals has received a new U.S. patent for its EXPAREL product, extending its protection until 2044. This strengthens the company's intellectual property portfolio.
The new patent extends the protection of Pacira's key product, EXPAREL, until 2044, which is likely to be viewed positively by investors as it secures long-term revenue potential and strengthens the company's competitive position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100